Announced
Completed
Synopsis
BioNTech and Fosun Pharma, two pharmaceutical companies, created the joint venture. Under the terms of the agreement, Fosun Pharma and BioNTech will work jointly on the development of BNT162 in China, conducting clinical trials by leveraging Fosun Pharma’s extensive clinical development, regulatory, and commercial capabilities in the country.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.